

# ORDINARY GENERAL MEETING

**MAY 27, 2020**

Ordinary general meeting in  
Scandion Oncology A/S

Date/time:

May 27, 2020 from 16.00 to  
18.00

Location: Online via  
Microsoft Teams and  
Symbion, meeting room M6

WELCOME TO

# ORDINARY GENERAL MEETING

**MAY 27, 2020**

## **For online access via Microsoft Teams**

Please switch off both video and microphone when you take part in the meeting.

If you want to ask a question at the general meeting, we request that you do so in writing via the chat function in Microsoft Teams.

You can ask your questions in writing during the general meeting up until agenda item 9.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

# SCO-101: OUTLINE OF THE ONGOING PHASE II PROGRAM

## Part 1

**SAFETY, TOXICITY AND EFFECT**  
(26 weeks)  
(First effect measure)

**DOSE  
SELECTION**

## Part 2

**EFFECT**  
(26 weeks)  
(Proof-of-Concept)

**End-points: Safety and objective response rate**



**12-18**

**PATIENTS WITH METASTATIC AND  
FOLFIRI RESISTANT COLORECTAL  
CANCER**



**25**

**PATIENTS WITH METASTATIC AND  
FOLFIRI RESISTANT COLORECTAL  
CANCER**



DAILY ORAL TREATMENT WITH **SCO-101** ONE WEEK BEFORE AND IN COMBINATION WITH FOLFIRI

**First Phase II study finalized Q1 2021**

# SCO-101: OUTLINE OF THE SECOND PHASE II PROGRAM

START OF PART 1, Q3, 2020

## Part 1

SAFETY, TOXICITY AND EFFECT  
(26 weeks)  
(First effect measure)

DOSE  
SELECTION  
RANDOMIZATION

## Part 2

EFFECT  
(52 weeks)  
(Proof-of-Concept)

End-points: Safety, PFS, OS and Clinical Benefit Rate

12-18

PATIENTS WITH METASTATIC  
PANCREATIC CANCER (PDAC)

SCO-101 + Nab-paclitaxel and gemcitabine

40

PATIENTS WITH METASTATIC PDAC

1.st line SCO-101 + Nab-paclitaxel and gemcitabine

20

PATIENTS WITH METASTATIC PDAC


1.st line Nab-paclitaxel and gemcitabine.

DAILY ORAL TREATMENT WITH SCO-101 4 DAYS BEFORE AND IN COMBINATION WITH CHEMOTHERAPY

# Agenda


- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

# Immune-oncology drugs given together with chemotherapy resulting in additive effects






# Chemotherapy resistance reduces the effect of the combination of chemotherapy and immune-oncology drugs



# SCO-101 restores chemotherapy sensitivity and restores the additive effect of combining chemotherapy and immune-oncology drugs



# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

# Share price development in Scandion Oncology A/S



# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

Re 2 The Board of Directors' report on the Company's business in the past year.

Comments or questions ?

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

## Re 3 Presentation of the revised annual report for approval

Annual report 2019 approved by the Board of Directors April 29, 2020 and published April 30, 2020

The annual report is based on

- Danish Financial Statements Act
- Unchanged accounting policies
- Going concern

State Authorised Public Accountant Deloitte has issued an unqualified (“clean”) opinion

“...the financial statements give a true and fair view of the Entity’s financial position at 31.12.2019 and of the results of its operations for the financial year 01.01.2019 - 31.12.2019.”



# Re 3 Presentation of the revised annual report for approval

## Key figures and selected financial posts

DKK	01-JAN-2019	01-JAN-2018
	31-DEC-2019	31-DEC-2018
Net sales	-	-
Operating profit/loss	(15,391,686)	(9,934,585)
Profit/loss before taxes	(15,554,551)	(9,957,906)
Profit/loss for the period	(12,183,591)	(8,182,558)
Total assets	19,902,610	13,562,750
Equity ratio (%)	92	93
Number of registered shares	19,052,241	11,907,651
Earnings per share	(0.64)	(0.85)

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

## Re. 4 Decision regarding use of surplus or coverage of losses according to the approved annual report

The Board of Directors proposes that the result for the period 1 January 2019 – 31 December 2019, minus DKK 12,183,591, is carried forward to the following year.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

## Re. 5 Election of members to the Board of Directors

The Board of Directors proposes that the existing Board of Directors is re-elected

Peter Høngård Andersen, Jørgen Vilhelm Løvenørn Bardenfleth, Carl Arne Krister Borreback, Thomas Feldthus, and Christian Vinding Thomsen

and that Bo Rode Hansen, whose CV is attached as schedule 1, is elected as a new board member.

**Bo Rode Hansen**  
**President and CEO**

**Genevant Sciences Inc.**

- **Former Global Head of Roche RNA Therapeutics**
- **Former General Manager of Roche Innovation Center Copenhagen**
- **Previous Head of Drug Discovery & Alliance at Santaris (acquired by Roche)**
- **20+ years in industry**



# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.



## Re. 6 Election of auditor

The Board of Directors proposes that the existing auditor (Deloitte Statsautoriseret Revisionspartnerselskab) is re-elected.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

## Re. 7 Proposal to authorize the Board of Directors to make one or more capital increases

The Board of Directors proposes that the general meeting authorizes the Board of Directors to decide, at one or more occasions, a capital increase pursuant to section 155 of the Danish Companies Act by offering the Company's shares to the public at the Spotlight Stock Market.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

## Re. 8 Proposal to authorize the Board of Directors to issue warrants.

The Board of Directors proposes that the general meeting authorizes the Board of Directors to decide, at one or more occasions, to issue warrants to the Company's executive board, employees and Board of Directors pursuant to section 155 of the Danish Companies Act which give the right to subscribe shares in the Company.

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.

## Re. 9 Proposal to adopt a voluntary arrangement for employee representation in the Company

The Board of Directors proposes to adopt a voluntary arrangement for employee representation in the Company which entails that the following wording is inserted as a new section 9.2 in the Company's articles of association:

*“In addition to the members of the Board of Directors elected by the general meeting, the employees of the Company may elect one employee representative to the Company's Board of Directors in accordance with the executive order of a voluntary employee representation scheme in public and private companies in force from time to time.”*

# Agenda

- 1) Election of chairman.
- 2) The Board of Directors' report on the Company's business in the past year.
- 3) Presentation of the revised annual report for approval.
- 4) Decision regarding use of surplus or coverage of losses according to the approved annual report.
- 5) Election of members to the Board of Directors.
- 6) Election of auditor.
- 7) Proposal to authorize the Board of Directors to make one or more capital increases.
- 8) Proposal to authorize the Board of Directors to issue warrants.
- 9) Proposal to adopt a voluntary arrangement for employee representation in the Company.
- 10) Any suggestions received.



Re. 10 Any suggestions received

No suggestions received.



End of slides and meeting